Figure 8. Impact of WIN 55,212-2 on basal and IL-1β-induced TF expression (A) and TF activity (B) in human blood monocytes.

Cells were incubated with WIN 55,212-2 at 10 μM for 8 h in the presence or absence of IL-1β. (C) Effect of AM-251 (CB₁ antagonist), AM-630 (CB₂ antagonist) and capsazepine (Capsa, TRPV1 antagonist) on the WIN 55,212-2-mediated inhibition of IL-1β-induced TF protein expression. Cells were pretreated with the respective receptor antagonist (all tested at a final concentration of 1 μM) for 1 h. IL-1β, WIN 55,212-2 (10 μM) or vehicle were added subsequently and the incubation was continued for 8 h. Percent control represents comparison with vehicle-treated cells (100%) in the absence of test substance. Values are means + SEM of n = 3 per group. **P < 0.01, ***P < 0.001 vs. corresponding vehicle control; ^###P < 0.001 vs. IL-1β, ANOVA plus post hoc Bonferroni test.